India, June 22 -- Aurobindo Pharma USA, a wholly owned subsidiary of Aurobindo Pharma, has received approval from the U.S. Federal Trade Commission (FTC) to proceed with its acquisition of Lannett Company LLC. The transaction, valued at $250 million on a cash-free, debt-free basis and including normalized working capital, is expected to be completed before the end of June 2026.
Lannett, a Pennsylvania-based generic pharmaceutical company, focuses on the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances. The acquisition is set to strengthen Aurobindo USA's presence in this segment while adding a U.S.-based manufacturing facility to its operations.
The deal includes Lannett's manufactu...